Drug design of cyclin-dependent kinase 2 inhibitor for melanoma from traditional Chinese medicine

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Tang, Hsin Chieh ^a   Chen, Calvin Yu Chian ^a,b,c  

^a ASIA UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CORYDALINE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 2 INHIBITOR; DINACICLIB; EVERNIC ACID; HIRSUTEINE; METHOXYMECAMBRIDINE; PLANT MEDICINAL PRODUCT; RESERPILINE; ROXBURGHINE X; STROBILANTHIN; TASPINE; TETRAHYDROPALMATINE; THALIGLUCINONE; UNCLASSIFIED DRUG; BERBERINE DERIVATIVE; ENZYME INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BAYES THEOREM; BINDING AFFINITY; BINDING SITE; CHINESE MEDICINE; CONTROLLED STUDY; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG SCREENING; ENZYME ACTIVITY; ENZYME INHIBITION; MELANOMA; MOLECULAR DOCKING; MOLECULAR DYNAMICS; SIMULATION; SUPPORT VECTOR MACHINE; SYSTEMS BIOLOGY; ANTAGONISTS AND INHIBITORS; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; HUMAN; PATHOLOGY; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

BERBERINE ALKALOIDS; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 2; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MEDICINE, CHINESE TRADITIONAL; MELANOMA; MOLECULAR DYNAMICS SIMULATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84904114051     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/798742     Document Type: Article

References (62)

1. Spencer S. L., Cappell S. D., Tsai F. C., Overton K. W., Wang L. Cl., Meyer T., The proliferation-quiescence decision is controlled by a bifurcation in CDK2 activity at mitotic exit. Cell 2013 155 2 369 383 10.1016/j.cell.2013. 08.062
2. Weinberg R. A., The retinoblastoma protein and cell cycle control. Cell 1995 81 3 323 330 2-s2.0-0029033861
3. Murray A. W., Kirschner M. W., Dominoes and clocks: the union of two views of the cell cycle. Science 1989 246 4930 614 621 2-s2.0-0024425274 (Pubitemid 19283352)
4. Hartwell L. H., Weinert T. A., Checkpoints: controls that ensure the order of cell cycle events. Science 1989 246 4930 629 634 2-s2.0-0024425887 (Pubitemid 19283354)
5. Kamb A., Gruis N. A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S. V., Stockert E., Day R. S. III, Johnson B. E., Skolnick M. H., A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994 264 5157 436 440 2-s2.0-0028121279
6. Dehay C., Kennedy H., Cell-cycle control and cortical development. Nature Reviews Neuroscience 2007 8 6 438 450 2-s2.0-34249004934 10.1038/nrn2097 (Pubitemid 46789227)
7. van den Heuvel S., Harlow E., Distinct roles for cyclin-dependent kinases in cell cycle control. Science 1993 262 5142 2050 2054 2-s2.0-0027742184 (Pubitemid 24041887)
8. Hartwell L. H., Hopfield J. J., Leibler S., Murray A. W., From molecular to modular cell biology. Nature 1999 402 supplement 6761 C47 C52 2-s2.0-0033518234
9. Bandara L. R., Adamczewski J. P., Hunt T., La Thangue N. B., Cyclin A and the retinoblastoma gene product complex with a common transcription factor. Nature 1991 352 6332 249 251 2-s2.0-0025917231 10.1038/352249a0 (Pubitemid 21912328)
10. Nurse P., Ordering S phase and M phase in the cell cycle. Cell 1994 79 4 547 550 2-s2.0-0027938207 10.1016/0092-8674(94)90539-8 (Pubitemid 24363797)
11. Harper J. W., Adami G. R., Wei N., Keyomarsi K., Elledge S. J., The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin- dependent kinases. Cell 1993 75 4 805 816 2-s2.0-0027496935 10.1016/0092-8674(93)90499-G (Pubitemid 23346377)
12. Waga S., Hannon G. J., Beach D., Stillman B., The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994 369 6481 574 578 2-s2.0-0028352434 10.1038/369574a0 (Pubitemid 24192528)
13. Xiong Y., Hannon G. J., Zhang H., Casso D., Kobayashi R., Beach D., p21 is a universal inhibitor of cyclin kinases. Nature 1993 366 6456 701 704 2-s2.0-0027717617 (Pubitemid 24036020)
14. Hannon G. J., Beach D., p15INK4B is a potential effector of TGF- β -induced cell cycle arrest. Nature 1994 371 6494 257 261 2-s2.0-0028168242
15. Hatada I., Mukai T., Genomic imprinting of p57(KIP2), a cyclin-dependent kinase inhibitor, in mouse. Nature Genetics 1995 11 2 204 206 2-s2.0-0028980026
16. Garraway L. A., Widlund H. R., Rubin M. A., Getz G., Berger A. J., Ramaswamy S., Beroukhim R., Milner D. A., Granter S. R., Du J., Lee C., Wagner S. N., Li C., Golub T. R., Rimm D. L., Meyerson M. L., Fisher D. E., Sellers W. R., Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005 436 7047 117 122 2-s2.0-21844478747 10.1038/nature03664 (Pubitemid 40966196)
17. Du J., Widlund H. R., Horstmann M. A., Ramaswamy S., Ross K., Huber W. E., Nishimura E. K., Golub T. R., Fisher D. E., Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 2004 6 6 565 576 2-s2.0-10944228764 10.1016/j.ccr.2004.10.014 (Pubitemid 40017700)
18. Bittner M., Meltzer P., Chen Y., Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000 406 6795 536 540 10.1038/35020115 (Pubitemid 30625740)
19. Miller A. J., Mihm M. C. Jr., Melanoma. The New England Journal of Medicine 2006 355 1 51 65 2-s2.0-33745684404 10.1056/NEJMra052166
20. Gogas H., Ioannovich J., Dafni U., Stavropoulou-Giokas C., Frangia K., Tsoutsos D., Panagiotou P., Polyzos A., Papadopoulos O., Stratigos A., Markopoulos C., Bafaloukos D., Pectasides D., Fountzilas G., Kirkwood J. M., Prognostic significance of autoimmunity during treatment of melanoma with interferon. The New England Journal of Medicine 2006 354 7 709 718 2-s2.0-32644454916 10.1056/NEJMoa053007 (Pubitemid 43247141)
21. Hodis E., Watson I. R., Kryukov G. V., Arold S. T., Imielinski M., Theurillat J.-P., Nickerson E., Auclair D., Li L., Place C., Dicara D., Ramos A. H., Lawrence M. S., Cibulskis K., Sivachenko A., Voet D., Saksena G., Stransky N., Onofrio R. C., Winckler W., Ardlie K., Wagle N., Wargo J., Chong K., Morton D. L., Stemke-Hale K., Chen G., Noble M., Meyerson M., Ladbury J. E., Davies M. A., Gershenwald J. E., Wagner S. N., Hoon D. S. B., Schadendorf D., Lander E. S., Gabriel S. B., Getz G., Garraway L. A., Chin L., A landscape of driver mutations in melanoma. Cell 2012 150 2 251 263 2-s2.0-84864258996 10.1016/j.cell.2012.06.024
22. Davies H., Bignell G. R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M. J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B. A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G. J., Bigner D. D., Palmleri G., Cossu A., Flanagan A., Nicholson A., Ho J. W. C., Leung S. Y., Yuen S. T., Weber B. L., Seigler H. F., Darrow T. L., Paterson H., Marais R., Marshall C. J., Wooster R., Stratton M. R., Futreal P. A., Mutations of the BRAF gene in human cancer. Nature 2002 417 6892 949 954 2-s2.0-18444374405 10.1038/nature00766 (Pubitemid 34716871)
23. Shi H., Moriceau G., Kong X., Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nature Communications 2012 3, article 724 10.1038/ncomms1727
24. Poulikakos P. I., Persaud Y., Janakiraman M., Kong X., Ng C., Moriceau G., Shi H., Atefi M., Titz B., Gabay M. T., Salton M., Dahlman K. B., Tadi M., Wargo J. A., Flaherty K. T., Kelley M. C., Misteli T., Chapman P. B., Sosman J. A., Graeber T. G., Ribas A., Lo R. S., Rosen N., Solit D. B., RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011 480 7377 387 390 2-s2.0-83455254767 10.1038/nature10662
25. Nazarian R., Shi H., Wang Q., Kong X., Koya R. C., Lee H., Chen Z., Lee M.-K., Attar N., Sazegar H., Chodon T., Nelson S. F., McArthur G., Sosman J. A., Ribas A., Lo R. S., Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010 468 7326 973 977 2-s2.0-78650303507 10.1038/nature09626
26. Johannessen C. M., Boehm J. S., Kim S. Y., Thomas S. R., Wardwell L., Johnson L. A., Emery C. M., Stransky N., Cogdill A. P., Barretina J., Caponigro G., Hieronymus H., Murray R. R., Salehi-Ashtiani K., Hill D. E., Vidal M., Zhao J. J., Yang X., Alkan O., Kim S., Harris J. L., Wilson C. J., Myer V. E., Finan P. M., Root D. E., Roberts T. M., Golub T., Flaherty K. T., Dummer R., Weber B. L., Sellers W. R., Schlegel R., Wargo J. A., Hahn W. C., Garraway L. A., COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010 468 7326 968 972 2-s2.0-78650309875 10.1038/nature09627
27. Stephens P. J., Tarpey P. S., Davies H., van Loo P., Greenman C., Wedge D. C., Nik-Zainal S., Martin S., Varela I., Bignell G. R., Yates L. R., Papaemmanuil E., Beare D., Butler A., Cheverton A., Gamble J., Hinton J., Jia M., Jayakumar A., Jones D., Latimer C., Lau K. W., McLaren S., McBride D. J., Menzies A., Mudie L., Raine K., Rad R., Chapman M. S., Teague J., Easton D., Langerød A., Karesen R., Schlichting E., Naume B., Sauer T., Ottestad L., Lee M. T. M., Shen C.-Y., Tee B. T. K., Huimin B. W., Broeks A., Vargas A. C., Turashvili G., Martens J., Fatima A., Miron P., Chin S.-F., Thomas G., Boyault S., Mariani O., Lakhani S. R., van de Vijver M., Van't Veer L., Foekens J., Desmedt C., Sotiriou C., Tutt A., Caldas C., Reis-Filho J. S., Aparicio S. A. J. R., Salomon A. V., Børresen-Dale A.-L., Richardson A. L., Campbell P. J., Futreal P. A., Stratton M. R., The landscape of cancer genes and mutational processes in breast cancer. Nature 2012 486 7403 400 404 2-s2.0-84861576201 10.1038/nature11017
28. Malumbres M., Barbacid M., Cell cycle, CDKs and cancer: a changing paradigm. Nature Reviews Cancer 2009 9 3 153 166 2-s2.0-60749109846 10.1038/nrc2602
29. Georgieva J., Sinha P., Schadendorf D., Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions. Journal of Clinical Pathology 2001 54 3 229 235 2-s2.0-0035092418 10.1136/jcp.54.3.229 (Pubitemid 32205046)
30. Abdullah C., Wang X., Becker D., Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma: functional analysis and molecular targeting of cyclin-dependent kinase family members in advanced melanoma. Cell Cycle 2011 10 6 977 988 2-s2.0-79952632471 10.4161/cc.10.6.15079
31. Desai B. M., Villanueva J., Nguyen T.-T. K., Lioni M., Xiao M., Kong J., Krepler C., Vultur A., Flaherty K. T., Nathanson K. L., Smalley K. S. M., Herlyn M., The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling. PLoS ONE 2013 8 3 2-s2.0-84875082183 10.1371/journal.pone.0059588 e59588
32. Wang C.-H., Lin W.-D., Tsai F.-J., Craniofacial dysmorphism, what is your diagnosis? BioMedicine 2012 2 2 49 50 2-s2.0-84862773772 10.1016/j.biomed.2012. 04.001
33. Liao W.-L., Tsai F.-J., Personalized medicine: a paradigm shift in healthcare. BioMedicine 2013 3 2 66 72 10.1016/j.biomed.2012.12.005
34. Chou I.-C., Lin W.-D., Wang C.-H., Chang Y.-T., Chin Z.-N., Tsai C.-H., Tsai F.-J., Möbius syndrome in a male with XX/XY mosaicism. BioMedicine 2013 3 2 102 104 2-s2.0-84876113931 10.1016/j.biomed.2013.02.002
35. Chang S.-S., Huang H.-J., Chen C. Y.-C., Two birds with one stone? Possible dual-targeting H1N1 inhibitors from traditional Chinese medicine. PLoS Computational Biology 2011 7 12 2-s2.0-84855282742 10.1371/journal.pcbi.1002315 e1002315
36. Chang T.-T., Sun M.-F., Chen H.-Y., Tsai F.-J., Fisher M., Lin J.-G., Chen C. Y.-C., Screening from the world's largest TCM database against H1N1 virus. Journal of Biomolecular Structure and Dynamics 2011 28 5 773 786 2-s2.0-79952209193
37. Tou W. I., Chang S.-S., Lee C.-C., Chen C. Y.-C., Drug design for neuropathic pain regulation from traditional Chinese medicine. Scientific Reports 2013 3, article 844 10.1038/srep00844 2-s2.0-84880533871
38. Tang H.-C., Chen C. Y.-C., Investigation of the novel lead of melanocortin 1 receptor for pigmentary disorders. Evidence-Based Complementary and Alternative Medicine 2014 2014 13 254678 10.1155/2014/254678
39. Tsai T.-Y., Chang K.-W., Chen C. Y.-C., iScreen: world's first cloud-computing web server for virtual screening and de novo drug design based on TCM database@Taiwan. Journal of Computer-Aided Molecular Design 2011 25 6 525 531 2-s2.0-80051545693 10.1007/s10822-011-9438-9
40. Chen K.-C., Sun M.-F., Yang S.-C., Chang S.-S., Chen H.-Y., Tsai F.-J., Chen C. Y.-C., Investigation into potent inflammation inhibitors from traditional Chinese medicine. Chemical Biology and Drug Design 2011 78 4 679 688 2-s2.0-80052619174 10.1111/j.1747-0285.2011.01202.x
41. Chen K.-C., Chen C. Y.-C., Stroke prevention by traditional Chinese medicine? A genetic algorithm, support vector machine and molecular dynamics approach. Soft Matter 2011 7 8 4001 4008 2-s2.0-79953746295 10.1039/c0sm01548b
42. Tian S., Wang J., Li Y., Xu X., Hou T., Drug-likeness analysis of traditional chinese medicines: prediction of drug-likeness using machine learning approaches. Molecular Pharmaceutics 2012 9 10 2875 2886 2-s2.0-84870177359 10.1021/mp300198d
43. Yang S.-C., Chang S.-S., Chen H.-Y., Chen C. Y.-C., Identification of potent EGFR inhibitors from TCM Database@Taiwan. PLoS Computational Biology 2011 7 10 2-s2.0-80055077153 10.1371/journal.pcbi.1002189 e1002189
44. Chen K.-C., Chang S.-S., Huang H.-J., Lin T.-L., Wu Y.-J., Chen C. Y.-C., Three-in-one agonists for PPAR-a, PPAR- γ and PPAR-d from traditional Chinese medicine. Journal of Biomolecular Structure & Dynamics 2012 30 6 662 683 2-s2.0-84871181814 10.1080/07391102.2012.689699
45. Chen C. Y.-C., TCM Database@Taiwan: the world's largest traditional Chinese medicine database for drug screening in silico. PLoS ONE 2011 6 1 2-s2.0-79251561193 10.1371/journal.pone.0015939 e15939
46. Byth K. F., Cooper N., Culshaw J. D., Heaton D. W., Oakes S. E., Minshull C. A., Norman R. A., Pauptit R. A., Tucker J. A., Breed J., Pannifer A., Rowsell S., Stanway J. J., Valentine A. L., Thomas A. P., Imidazo[1,2-b] pyridazines: a potent and selective class of cyclin-dependent kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 2004 14 9 2249 2252 2-s2.0-11144354321 10.1016/j.bmcl.2004.02.008 (Pubitemid 38481399)
47. Chen C. Y.-C., Tou W. I., How to design a drug for the disordered proteins? Drug Discovery Today 2013 18 910 915 10.1016/j.drudis.2013.04.008
48. Tou W. I., Chen C. Y.-C., May disordered protein cause serious drug side effect? Drug Discovery Today 2014 19 4 367 372 10.1016/j.drudis.2013.10.020
49. Keller T. H., Pichota A., Yin Z., A practical view of "druggability'. Current Opinion in Chemical Biology 2006 10 4 357 361 2-s2.0-33746071900 10.1016/j.cbpa.2006.06.014 (Pubitemid 44080649)
50. Ganesan A., The impact of natural products upon modern drug discovery. Current Opinion in Chemical Biology 2008 12 3 306 317 2-s2.0-44949134801 10.1016/j.cbpa.2008.03.016
51. Brooks B. R., Brooks C. L. III, Mackerell A. D. Jr., Nilsson L., Petrella R. J., Roux B., Won Y., Archontis G., Bartels C., Boresch S., Caflisch A., Caves L., Cui Q., Dinner A. R., Feig M., Fischer S., Gao J., Hodoscek M., Im W., Kuczera K., Lazaridis T., Ma J., Ovchinnikov V., Paci E., Pastor R. W., Post C. B., Pu J. Z., Schaefer M., Tidor B., Venable R. M., Woodcock H. L., Wu X., Yang W., York D. M., Karplus M., CHARMM: the biomolecular simulation program. Journal of Computational Chemistry 2009 30 10 1545 1614 2-s2.0-67650500988 10.1002/jcc.21287
52. Chen C. Y.-C., A novel integrated framework and improved methodology of computer-aided drug design. Current Topics in Medicinal Chemistry 2013 13 9 965 988 2-s2.0-84878775187 10.2174/1568026611313090002
53. Chen C. Y.-C., Weighted equation and rules-a novel concept for evaluating protein-ligand interaction. Journal of Biomolecular Structure & Dynamics 2009 27 3 271 282 2-s2.0-70349903395
54. Tripathi S. K., Muttineni R., Singh S. K., Extra precision docking, free energy calculation and molecular dynamics simulation studies of CDK2 inhibitors. Journal of Theoretical Biology 2013 334 87 100 2-s2.0-84880286488 10.1016/j.jtbi.2013.05.014
55. Khan M. T. H., Predictions of the ADMET properties of candidate drug molecules utilizing different QSAR/QSPR modelling approaches. Current Drug Metabolism 2010 11 4 285 295 2-s2.0-77953314142 10.2174/138920010791514306
56. van der Spoel D., Lindahl E., Hess B., Groenhof G., Mark A. E., Berendsen H. J. C., GROMACS: fast, flexible, and free. Journal of Computational Chemistry 2005 26 16 1701 1718 2-s2.0-27344454932 10.1002/jcc.20291 (Pubitemid 43076182)
57. Maiorov V. N., Crippen G. M., Size-independent comparison of protein three-dimensional structures. Proteins: Structure, Function and Genetics 1995 22 3 273 283 2-s2.0-0029057126 10.1002/prot.340220308
58. Chovancova E., Pavelka A., Benes P., Strnad O., Brezovsky J., Kozlikova B., Gora A., Sustr V., Klvana M., Medek P., Biedermannova L., Sochor J., Damborsky J., CAVER 3.0: a tool for the analysis of transport pathways in dynamic protein structures. PLoS Computational Biology 2012 8 10 2-s2.0-84868156224 10.1371/journal.pcbi.1002708 e1002708
59. Kumar A. P., Bhaskaran S., Ganapathy M., Crosby K., Davis M. D., Kochunov P., Schoolfield J., Yeh I.-T., Troyer D. A., Ghosh R., Akt/cAMP-responsive element binding protein/cyclin D1 network: a novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by nexrutine, a Phellodendron amurense bark extract. Clinical Cancer Research 2007 13 9 2784 2794 2-s2.0-34249089950 10.1158/1078-0432.CCR-06-2974 (Pubitemid 46788048)
60. James M. A., Fu H., Liu Y., Chen D.-R., You M., Dietary administration of berberine or Phellodendron amurense extract inhibits cell cycle progression and lung tumorigenesis. Molecular Carcinogenesis 2011 50 1 1 7 2-s2.0-78650185177 10.1002/mc.20690
61. Jin G.-B., Hong T., Inoue S., Urano T., Cho S., Otsu K., Kitahara M., Ouchi Y., Cyong J.-C., Augmentation of immune cell activity against tumor cells by Rauwolfia radix. Journal of Ethnopharmacology 2002 81 3 365 372 2-s2.0-0035996873 10.1016/S0378-8741(02)00123-X (Pubitemid 34786322)
62. Gao J.-L., Shi J.-M., He K., Zhang Q.-W., Li S.-P., Lee S. M.-Y., Wang Y.-T., Yanhusuo extract inhibits metastasis of breast cancer cells by modulating mitogen-activated protein kinase signaling pathways. Oncology Reports 2008 20 4 819 824 2-s2.0-54949114297 10.3892/or-00000079